RNA, U6 small nuclear 853, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-853P profile across patient tissues and cancer cell-line models. RNU6-853P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6-853P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, RNU6-853P RNA expression shows 11,165 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, LUSC, and PDAC as cancer lineages where RNU6-853P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-853P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-853P survival associations across molecular data types. RNU6-853P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-853P RNA expression–survival associations across cancer types. High RNU6-853P expression shows unfavorable associations in KIRC, COAD, KICH and HNSC, but favorable associations in BLCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6-853P RNA expression.
This table summarizes RNU6-853P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-853P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-853P shows lower tumor expression in ESCA and KIRP and higher tumor expression in LUSC and CHOL. The LUSC box plot shows higher RNU6-853P RNA expression in tumor versus normal tissue (log2 FC = +0.229, t-test p = .022).
This table shows molecular features associated with RNU6-853P in patient tissues and cancer cell lines. In patient samples, RNU6-853P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
